Terms: = Prostate cancer AND MDM2, HDM2, 4193, ENSG00000135679, HDMX, MGC71221, hdm2, Q00987
243 results:
1. TrkA promotes mdm2-mediated AGPS ubiquitination and degradation to trigger prostate cancer progression.
Zhang Y; Huang Z; Li K; Xie G; Feng Y; Wang Z; Li N; Liu R; Ding Y; Wang J; Yang J; Jia Z
J Exp Clin Cancer Res; 2024 Jan; 43(1):16. PubMed ID: 38200609
[TBL] [Abstract] [Full Text] [Related]
2. Design, Synthesis and Antitumor Activity of 1
Wang C; Zhu M; Long X; Wang Q; Wang Z; Ouyang G
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240028
[TBL] [Abstract] [Full Text] [Related]
3. Synthesis and biological evaluation of dual mdm2/XIAP inhibitors based on the tetrahydroquinoline scaffold.
Albadari N; Xie Y; Liu T; Wang R; Gu L; Zhou M; Wu Z; Li W
Eur J Med Chem; 2023 Jul; 255():115423. PubMed ID: 37130471
[TBL] [Abstract] [Full Text] [Related]
4. Inclusion of Nitrofurantoin into the Realm of cancer Chemotherapy via Biology-Oriented Synthesis and Drug Repurposing.
Elzahhar PA; Nematalla HA; Al-Koussa H; Abrahamian C; El-Yazbi AF; Bodgi L; Bou-Gharios J; Azzi J; Al Choboq J; Labib HF; Kheir WA; Abu-Serie MM; Elrewiny MA; El-Yazbi AF; Belal ASF
J Med Chem; 2023 Apr; 66(7):4565-4587. PubMed ID: 36921275
[TBL] [Abstract] [Full Text] [Related]
5. Blockage of mdm2-mediated p53 ubiquitination by yuanhuacine restrains the carcinogenesis of prostate carcinoma cells by suppressing LncRNA LINC00665.
Yan M; Li X; Gu J; Gao G; Wu Z; Xue P
J Biochem Mol Toxicol; 2023 Mar; 37(3):e23265. PubMed ID: 36416364
[TBL] [Abstract] [Full Text] [Related]
6. Novel spirooxindole based benzimidazole scaffold: In vitro, nanoformulation and in vivo studies on anticancer and antimetastatic activity of breast adenocarcinoma.
Barakat A; Alshahrani S; Mohammed Al-Majid A; Saleh Alamary A; Haukka M; Abu-Serie MM; Dömling A; Mazyed EA; Badria FA; El-Senduny FF
Bioorg Chem; 2022 Dec; 129():106124. PubMed ID: 36174446
[TBL] [Abstract] [Full Text] [Related]
7. Novel AR/AR-V7 and Mnk1/2 Degrader, VNPP433-3β: Molecular Mechanisms of Action and Efficacy in AR-Overexpressing Castration Resistant prostate cancer In Vitro and In Vivo Models.
Thomas E; Thankan RS; Purushottamachar P; Huang W; Kane MA; Zhang Y; Ambulos NP; Weber DJ; Njar VCO
Cells; 2022 Aug; 11(17):. PubMed ID: 36078112
[TBL] [Abstract] [Full Text] [Related]
8. De Novo Design of an Androgen Receptor DNA Binding Domain-Targeted peptide PROTAC for prostate cancer Therapy.
Ma B; Fan Y; Zhang D; Wei Y; Jian Y; Liu D; Wang Z; Gao Y; Ma J; Chen Y; Xu S; Li L
Adv Sci (Weinh); 2022 Oct; 9(28):e2201859. PubMed ID: 35971165
[TBL] [Abstract] [Full Text] [Related]
9. lncRNA MNX1‑AS1 promotes prostate cancer progression through regulating miR‑2113/mdm2 axis.
Liang D; Tian C; Zhang X
Mol Med Rep; 2022 Jul; 26(1):. PubMed ID: 35616155
[TBL] [Abstract] [Full Text] [Related]
10. A review on the genetic polymorphisms and susceptibility of cancer patients in Bangladesh.
Babu G; Bin Islam S; Khan MA
Mol Biol Rep; 2022 Jul; 49(7):6725-6739. PubMed ID: 35277785
[TBL] [Abstract] [Full Text] [Related]
11. Clinical considerations for the design of PROTACs in cancer.
Nieto-Jiménez C; Morafraile EC; Alonso-Moreno C; Ocaña A
Mol Cancer; 2022 Mar; 21(1):67. PubMed ID: 35249548
[TBL] [Abstract] [Full Text] [Related]
12. Therapeutic potential of p53 reactivation in prostate cancer: Strategies and opportunities.
Kumari S; Sharma V; Tiwari R; Maurya JP; Subudhi BB; Senapati D
Eur J Pharmacol; 2022 Mar; 919():174807. PubMed ID: 35151649
[TBL] [Abstract] [Full Text] [Related]
13. K
Ohya S; Kajikuri J; Endo K; Kito H; Matsui M
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948357
[TBL] [Abstract] [Full Text] [Related]
14. Synthesis and Biological Evaluation of S-, O- and Se-Containing Dispirooxindoles.
Kukushkin M; Novotortsev V; Filatov V; Ivanenkov Y; Skvortsov D; Veselov M; Shafikov R; Moiseeva A; Zyk N; Majouga A; Beloglazkina E
Molecules; 2021 Dec; 26(24):. PubMed ID: 34946727
[TBL] [Abstract] [Full Text] [Related]
15. Molecular imaging and treatment of PSMA-positive prostate cancer with
Jiao Y; Xu P; Luan S; Wang X; Gao Y; Zhao C; Fu P
Nucl Med Biol; 2022; 104-105():28-37. PubMed ID: 34847481
[TBL] [Abstract] [Full Text] [Related]
16. Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC.
Zhang B; Zhang M; Yang Y; Li Q; Yu J; Zhu S; Niu Y; Shang Z
Oncogene; 2022 Jan; 41(3):387-399. PubMed ID: 34759344
[TBL] [Abstract] [Full Text] [Related]
17. Stereoselective Synthesis of the Di-Spirooxindole Analogs Based Oxindole and Cyclohexanone Moieties as Potential Anticancer Agents.
Al-Majid AM; Ali M; Islam MS; Alshahrani S; Alamary AS; Yousuf S; Choudhary MI; Barakat A
Molecules; 2021 Oct; 26(20):. PubMed ID: 34684885
[TBL] [Abstract] [Full Text] [Related]
18. Genetic and epigenetic bases of prostate tumor cell radioresistance.
Kutilin D
Klin Onkol; 2021; 34(3):220-234. PubMed ID: 34362257
[TBL] [Abstract] [Full Text] [Related]
19. Genetic and epigenetic bases of prostate tumor cell radioresistance.
Kutilin Denis
Ceska Gynekol; 2021; 86(3):220-234. PubMed ID: 34192880
[TBL] [Abstract] [Full Text] [Related]
20. Ionizing Radiation Combined with PARP1 Inhibitor Reduces Radioresistance in prostate cancer with RB1/TP53 Loss.
Fan Y; Fan H; Quan Z; Wu X
Cancer Invest; 2021 May; 39(5):423-434. PubMed ID: 33683975
[TBL] [Abstract] [Full Text] [Related]
[Next]
